PANERB study: Panitumumab after cetuximab-based regimen failure.

摘要: e14000 Background: Metastatic colorectal cancer management (MRCC) has been clearly improved by targeted therapies such as anti-HER1 drugs. The evaluation of the use in real world is strategic to assess health politics. OMIT Bretagne-Pays de Loire a network private and public centers. Cohorts patients concerning Folfiri Bevacizumab treatment (Metges et al, ASCO GI 2009), cost (Grude 2009) AvastErb study ESMO have previously published this topic. Panitumumab cetuximab can be used MRCC but no series available evaluate panitumumab monotherapy (PM) after irinotecan based regimen (CIBR) failure. Methods: aim succession then regimens homogenous kras wild-type unresectable MRCC. Sex, age, localization primary, successive chemotherapeutic regimens, toxicities, response rate,...